EVO (Evotec SE) Cyclically Adjusted PB Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EVO Evotec SE EVO
54 GF Score
Price $1.54
GF Value $3.32
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Evotec SE Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Evotec SE  (NAS:EVO) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Evotec SE Cyclically Adjusted PB Ratio Related Terms


Evotec SE Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Evotec SE's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evotec SE Cyclically Adjusted PB Ratio Chart

Evotec SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.15 3.91 4.90 1.58 1.08

Evotec SE Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.65 1.39 1.16 0.92 1.02

EVO vs ZTS, UTHR, VTRS: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evotec SE Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evotec SE's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Evotec SE's Cyclically Adjusted PB Ratio falls into.


EVO
54GF Score
Evotec SE EVO
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evotec SE Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Evotec SE's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Evotec SE's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.142/131.3638*131.3638
=2.142

Current CPI (Jun. 2026) = 131.3638.

Evotec SE Quarterly Data

Book Value per Share CPI Adj_Book
201609 0.820 101.017 1.066
201612 0.850 101.217 1.103
201703 1.145 101.417 1.483
201706 1.224 102.117 1.575
201709 1.281 102.717 1.638
201712 1.353 102.617 1.732
201803 1.417 102.917 1.809
201806 1.399 104.017 1.767
201809 1.538 104.718 1.929
201812 1.632 104.217 2.057
201903 1.683 104.217 2.121
201906 1.671 105.718 2.076
201909 1.683 106.018 2.085
201912 1.777 105.818 2.206
202003 1.778 105.718 2.209
202006 1.768 106.618 2.178
202009 1.828 105.818 2.269
202012 2.708 105.518 3.371
202103 2.836 107.518 3.465
202106 3.076 108.486 3.725
202109 3.489 109.435 4.188
202112 4.442 110.384 5.286
202203 4.124 113.968 4.753
202206 3.773 115.760 4.282
202209 3.406 118.818 3.766
202212 3.585 119.345 3.946
202303 122.402 0.000
202306 3.620 123.140 3.862
202309 3.413 124.195 3.610
202312 3.496 123.773 3.710
202403 3.377 125.038 3.548
202406 3.057 125.882 3.190
202409 3.048 126.198 3.173
202412 2.780 127.041 2.875
202503 2.774 127.779 2.852
202506 2.795 128.412 2.859
202509 2.647 129.255 2.690
202512 2.692 129.361 2.734
202603 2.270 131.258 2.272
202606 2.142 131.364 2.142

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Evotec SE (EVO) Overvalued in 2026?

Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued. The current stock price of $1.54 is trading 53.6% below its estimated GF Value™ of $3.32. GuruFocus considers Evotec SE to be Possible Value Trap.

Key valuation signals for EVO:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: $3.32 vs. price of $1.54 (53.6% below fair value)
  • GF Score™: 54/100 with 5 warning signs

No single metric tells the full story. See the EVO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Evotec SE Business Description

Address Essener Bogen 7, 22419 Hamburg, Hamburg, DEU, 22419
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
54GF Score

Get the complete analysis for EVO

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.54
Price
$3.32
GF Value